Equities Analysts Offer Predictions for Bruker Q2 Earnings

Bruker Corporation (NASDAQ:BRKR) – Leerink Partnrs upped their Q2 2026 earnings estimates for Bruker in a note issued to investors on Monday, November 3rd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.48 per share for the quarter, up from their prior forecast of $0.45. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2026 earnings at $0.62 EPS, FY2026 earnings at $2.44 EPS and FY2027 earnings at $2.84 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. The firm had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS.

Other research analysts have also issued reports about the company. Wells Fargo & Company dropped their price objective on Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. Cowen reissued a “hold” rating on shares of Bruker in a report on Tuesday. TD Cowen upped their price objective on shares of Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a research note on Tuesday. Finally, Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $48.30.

Bruker Trading Up 1.6%

Shares of BRKR opened at $39.93 on Thursday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market cap of $6.06 billion, a PE ratio of 76.79, a PEG ratio of 5.31 and a beta of 1.26. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64. The stock has a 50 day simple moving average of $35.02 and a 200-day simple moving average of $37.08.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BRKR. Nisa Investment Advisors LLC boosted its position in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after buying an additional 487 shares during the last quarter. Allworth Financial LP raised its position in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after acquiring an additional 364 shares during the last quarter. Huntington National Bank lifted its stake in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 645 shares during the period. Spire Wealth Management bought a new position in Bruker in the second quarter valued at about $32,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 745 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.30% of the company’s stock.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s payout ratio is currently -125.00%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.